• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Case for interdisciplinary rheumatologic–ophthalmologic collaboration to optimize patient care

News
Article

Investigators pointed out that spondyloarthritis (SpA) and Behçet’s disease are typical diseases that require the expertise of rheumatologists and ophthalmologists.

(Image Credit: AdobeStock/s_l)

(Image Credit: AdobeStock/s_l)

Austrian investigators advise establishing an interdisciplinary setting, ie, rheumatologic–ophthalmologic, to improve the management of patients with rheumatic diseases.1 The investigators were led by first author Ralf Altenberger, MD, from Clinic II, Department of Internal Medicine, Medical University of Innsbruck, and colleagues from the Department of Ophthalmology and Optometry, Medical University of Innsbruck, Austria.

The investigators pointed out that spondyloarthritis (SpA) and Behçet’s disease are typical diseases that require the expertise of rheumatologists and ophthalmologists. Uveitis is a recognized extraskeletal manifestation of both SpA2 and Behcet’s disease.3 However, at least 10 other inflammatory rheumatic diseases are potentially associated with uveitis.4

They commented, “Additionally, there are many more ocular manifestations that possibly present with a rheumatic disease, from keratoconjunctivitis sicca in Sjögren’s syndrome to visual disturbances and even visual loss in giant cell arteritis. Thus, eye involvement in rheumatic diseases may have a dramatic impact on the prognosis and quality of life of patients with rheumatic diseases. In contrast, other eye diseases may occur independently of rheumatic disease.”

Because there is little data on the prevalence of ocular diseases in patients with rheumatologic diseases, the aims of this study were two-fold: to provide data on the retrospectively assessed prevalence of ophthalmologic diseases in real-world data from a rheumatology outpatient clinic and to consider the role of a multi-disciplinary rheumatology–ophthalmology clinic.

The investigators performed a chart review in this retrospective observational cohort study. They reported the following: Of the 1,529 rheumatic outpatients, 26.9% had an ophthalmic diagnosis, whereas, from a rheumatologic perspective, inflammatory non-infectious diagnoses dominated at 71.7%. From an ophthalmologic perspective, diagnoses without inflammatory pathophysiologic backgrounds dominated at 54.9%. An inflammatory non-infectious ophthalmologic disease was diagnosed in 24.2% of patients with rheumatoid arthritis and 29.3% of patients with peripheral SpA. Not 1 patient with rheumatoid arthritis was diagnosed with anterior uveitis; however, 16.5% of patients with SpA were diagnosed with anterior uveitis, which was significant (p < 0.001). The prevalence of uveitis was 16.3% in axial and 20.1% in peripheral SpA.

The investigators concluded that an interdisciplinary rheumatologic–ophthalmologic setting appears justified to further improve the management of patients with rheumatic diseases.

References:
  1. Altenberger R, Rauchegger T, Haas G, et al. Eye disease in patients with rheumatic diseases: a retrospective observational cohort study. J Clin Med. 2023;12:7510; https://doi.org/10.3390/jcm12247510
  2. Dougados M, Baeten D. Spondyloarthritis. Lancet 2011:377:2127–2137.
  3. Davatchi F, Chams-Davatchi C, Shams H, et al. Behcet’s disease: epidemiology, clinical manifestations, and diagnosis. Expert Rev. Clin. Immunol. 2017;13:57–65.
  4. Petris CK Almony, A. Ophthalmic manifestations of rheumatologic disease: diagnosis and management. MO Med. 2012;109:53–58.
Related Videos
Video 6 - "Impact Of Durable Agents on Treatment Burden and Quality of Life in Retinal Diseases"
Video 5 - "Evolving Role of Steroids and Laser In DME"
Video 4 - "A Case of a DME Patient Achieving Extended Treatment Interval with New Therapy"
Video 3 - "Treating a DME Patient Lost to Follow-Up with a Highly Durable Agent"
Video 2 - "A Case of Neovascular AMD with Persistent Subretinal Fluid"
Video 1 - "A Case of Neovascular AMD With Treatment-Resistant Pigment Epithelium Detachment"
Video 1 - "Challenging the Definition of Dry Eye- Interpreting Diagnostic Tests"
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
© 2024 MJH Life Sciences

All rights reserved.